GLP-1 RA users were more likely to receive medical therapy for HF [mineralocorticoid receptor antagonists, sodium-glucose cotransporter 2 inhibitors (SGLT2i), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitor, and HF devices], and followed up in nurse-led clinics and speciality vs. primary care. Here, GLP1R is linked to hydrops fetalis.